Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team. Dinkelborg K, et al. Among authors: deterding k. Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602. Epub 2023 May 15. Liver Int. 2023. PMID: 37183524 Clinical Trial.
Present and future therapy for hepatitis C virus.
Cornberg M, Deterding K, Manns MP. Cornberg M, et al. Among authors: deterding k. Expert Rev Anti Infect Ther. 2006 Oct;4(5):781-93. doi: 10.1586/14787210.4.5.781. Expert Rev Anti Infect Ther. 2006. PMID: 17140355 Review.
Steroid treatment for severe acute cryptogenic hepatitis.
Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP, Wedemeyer H, Bahr MJ. Potthoff A, et al. Among authors: deterding k. Z Gastroenterol. 2007 Jan;45(1):15-9. doi: 10.1055/s-2006-927280. Z Gastroenterol. 2007. PMID: 17236116
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A, Deterding K, Trautwein C, Rifai K, Manns MP, Wedemeyer H. Potthoff A, et al. Among authors: deterding k. Eur J Gastroenterol Hepatol. 2007 Oct;19(10):906-9. doi: 10.1097/MEG.0b013e3282094160. Eur J Gastroenterol Hepatol. 2007. PMID: 17873617
Clearance of chronic HCV infection during acute delta hepatitis.
Deterding K, Pothakamuri SV, Schlaphoff V, Hadem J, Metzler F, Bahr MJ, Manns MP, Cornberg M, Wedemeyer H. Deterding K, et al. Infection. 2009 Apr;37(2):159-62. doi: 10.1007/s15010-007-7204-7. Epub 2007 Dec 14. Infection. 2009. PMID: 18084714
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C; Hep-Net B/C Co-infection Study Group. Potthoff A, et al. Among authors: deterding k. J Hepatol. 2008 Nov;49(5):688-94. doi: 10.1016/j.jhep.2008.03.028. Epub 2008 Apr 29. J Hepatol. 2008. PMID: 18490077 Clinical Trial.
Prevalence of HBV genotypes in Central and Eastern Europe.
Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd'áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H. Deterding K, et al. J Med Virol. 2008 Oct;80(10):1707-11. doi: 10.1002/jmv.21294. J Med Virol. 2008. PMID: 18712830
112 results